Evidence map›Paper›PMID 36442827›Full record

Observational studyJournal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy2023

Humoral response and safety of the BNT162b2 and mRNA-1273 COVID-19 vaccines in allogeneic hematopoietic stem cell transplant recipients: An observational study.

Masashi Nishikubo, Yoshimitsu Shimomura, Hayato Maruoka, Seiko Nasu, Tomomi Nishioka, Kenji Sakizono, Satoshi Mitsuyuki, Tomoyo Kubo, Naoki Okada, Daishi Nakagawa and 11 more

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it, 5 citations in OpenAlex.

  1. Vaccination of Adults With Cancer: ASCO Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Guideline
  2. Pooled it
  3. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Masashi NishikuboDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Yoshimitsu ShimomuraDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan; Department of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Osaka, 565-0871, Japan. Electronic address: shimomura_0119@yahoo.co.jp.
Hayato MaruokaDepartment of Clinical Laboratory, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Seiko NasuDepartment of Clinical Laboratory, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Tomomi NishiokaLSI Medience Laboratory, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Kenji SakizonoDepartment of Clinical Laboratory, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Satoshi MitsuyukiDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Tomoyo KuboDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Naoki OkadaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Daishi NakagawaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Kimimori KamijoDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Hiroharu ImotoDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Ryusuke YamamotoDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Yuya NagaiDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Nobuhiro HiramotoDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Satoshi YoshiokaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Noboru YonetaniDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Akiko MatsushitaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Chisato MiyakoshiDepartment of Research Support, Center for Clinical Research and Innovation, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Asako DoiDepartment of Infectious Diseases, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Takayuki IshikawaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan.
Kobe City Medical Center General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe effectiveness of mRNA COVID-19 vaccines and the optimal timing of vaccine administration in allogeneic hematopoietic stem cell transplantation (Allo-HSCT) recipients remains inadequately investigated. We examine the effectiveness and safety of mRNA COVID-19 vaccines in allo-HSCT recipients.

methodThis prospective observational study included 44 allo-HSCT recipients and 38 healthy volunteers. The proportion of subjects acquiring anti-S1 IgG antibodies were considered as the primary endpoint. The occurrence of adverse events after vaccination and objective deterioration of chronic graft-versus-host disease (GVHD) were defined as secondary endpoints. In addition, we compared the geometric mean titers (GMT) of anti-S1 antibody titers in subgroups based on time interval between transplantation and vaccination.

resultsA humoral response to the vaccine was evident in 40 (91%) patients and all 38 healthy controls. The GMT of anti-S1 titers in patients and healthy controls were 277 (95% confidence interval [CI]: 120-643) BAU/mL and 532 (95% CI 400-708) BAU/mL, respectively. (p = 0.603). A short time interval between transplantation and vaccination (≤6 months) was associated with low anti-S1 IgG antibody titers. No serious adverse events and deterioration of chronic GVHD were observed. Only one case of new development of mild chronic GVHD was recorded.

conclusionMessenger RNA COVID-19 vaccines induce humoral responses in allo-HSCT recipients and can be administered safely.

Indexed as

Bronchiolitis Obliterans SyndromeCOVID-19COVID-19 VaccinesHematopoietic Stem Cell Transplantation2019-nCoV Vaccine mRNA-1273Antibodies, ViralBNT162 VaccineHumansProspective StudiesRNA, MessengerVaccination2019-nCoV Vaccine mRNA-1273Antibodies, ViralBNT162 VaccineCOVID-19 VaccinesRNA, MessengerAllogeneicCOVID-19SARS-CoV-2TransplantationVaccine

Identifiers

PMID36442827
PMCPMC9699714
OpenAlexW4310068655

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.